Latest News and Press Releases

Media ReleaseCOPENHAGEN, Denmark; June 2, 2025 New data showed that rinatabart sesutecan (Rina-S®) 100 mg/m2 led to a confirmed objective response rate (ORR) of 50.0 percent, including two complete...

Company Announcement COPENHAGEN, Denmark; June 2, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million...

Media ReleaseCOPENHAGEN, Denmark; May 27, 2025Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will participate in a fireside chat at the 46th Goldman Sachs...

Company Announcement COPENHAGEN, Denmark; May 26, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million...

Media ReleaseCOPENHAGEN, Denmark; May 22, 2025 First presentation of results from Phase 1/2 clinical trial of investigational rinatabart sesutecan (Rina-S®) in patients with recurrent/advanced...

Media ReleaseCOPENHAGEN, Denmark; May 21, 2025Genmab A/S (Nasdaq: GMAB) announced today that its Chief Development Officer Judith Klimovsky will participate in a fireside chat at the 2025 Jefferies...

Company Announcement COPENHAGEN, Denmark; May 20, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 1,746 shares as a consequence of the exercise of employee warrants. The increase...

Company Announcement COPENHAGEN, Denmark; May 19, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million...

Media ReleaseCOPENHAGEN, Denmark; May 14, 2025 Data from 14 abstracts highlight the depth, breadth, and strength of Genmab’s comprehensive epcoritamab development program across multiple patient...

Company Announcement COPENHAGEN, Denmark; May 12, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million...